Trials / Completed
CompletedNCT02243150
Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1
First-In-Human Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of G1T28-1 in Healthy Male and Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- G1 Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This first-in-human (FIH) study will provide the first safety, PK, and PD data of G1T28-1 in humans and will allow further development of G1T28 1 in patients with cancer to reduce chemotherapy-induced myelosuppression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | G1T28-1 (CDK 4/6 Inhibitor) | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2015-02-01
- Completion
- 2015-12-18
- First posted
- 2014-09-17
- Last updated
- 2018-12-17
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02243150. Inclusion in this directory is not an endorsement.